Anti-doping labs test urine. It is the workhorse fluid of drug screening in sport, cheap to collect and easy to demand at scale. Retatrutide, the experimental triple-hormone weight-loss drug that has posted some of the largest fat-loss numbers ever seen in a trial, does not show up in urine at all. A Brazilian doping-control lab dosed four volunteers and looked in both blood and urine. In blood the drug lingered for weeks. In urine it was never detectable, not in a single sample.
The study, published in Rapid Communications in Mass Spectrometry ↗, came out of LADETEC, the doping-control laboratory at the Federal University of Rio de Janeiro. Four participants injected 2 milligrams of retatrutide under the skin on day one and again on day seven, the kind of low starting dose a real user would take. The lab then built separate liquid-chromatography mass-spectrometry methods for plasma and for urine and ran samples out over weeks.
The two fluids told opposite stories. In plasma the method could see down to 6.14 nanograms per milliliter, a few billionths of a gram in each milliliter of blood, and the drug stayed above that line for roughly 56 days after the last injection. Almost two months. In urine the method was actually more sensitive, detecting down to 2.44 nanograms per milliliter, and it still came up empty every time. No intact drug, no measured breakdown product, nothing, across the whole collection window.
Why the blood holds it and the urine never sees it
Retatrutide is a peptide, a small engineered protein, and that is the whole explanation. Molecules that size are not filtered out intact by the kidney the way small-molecule drugs are. They are taken apart by the body's ordinary protein-breakdown machinery, so the parent compound and its fragments do not survive the trip into urine in a form a test can catch. The injection also behaves like a slow-release depot under the skin, feeding the drug into the blood unevenly rather than in a clean rise and fall, which is why the plasma curve the authors describe is bumpy rather than a tidy single peak.
For a testing agency that is a hard constraint, not a tuning problem. You cannot lower a urine method's detection limit far enough to find something that is not there. If a sport wanted to screen for retatrutide, the blood is the only window, and blood collection is slower, more invasive, and less routine than the urine cup.
The regulatory gap it points at
Retatrutide is not an approved medicine anywhere. It is still in clinical trials. That status matters here because the authors note it would fall under the World Anti-Doping Agency's category for substances with no current regulatory approval for human use, the bucket that is prohibited at all times regardless of whether a specific drug is named. A lean, appetite-blunting agent that is easy to obtain on the gray market and invisible to the standard urine screen is exactly the profile that worries the people who write those rules.
The finding is narrow and the sample is tiny, four people, one dose level. It does not establish how retatrutide would look after months of use or at the higher maintenance doses trials are testing. What it does is close off a route: the cheap, scalable urine test is a dead end for this molecule, and any monitoring will have to be built in blood.
The drug earns its potency by hitting three receptors at once. Retatrutide, known in development as LY3437943, is a triple agonist at the GLP-1 receptor ↗, the GIP receptor ↗, and the glucagon receptor ↗, the same gut-and-metabolism switches that the single and dual agonists pull. Retatrutide ↗ pulls all three, which is why it moves weight so hard, and, as this lab showed, why catching it will take a blood draw.